Vor Biopharma Inc. (VOR)
| Market Cap | 779.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -695.98M |
| Shares Out | 54.19M |
| EPS (ttm) | -70.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 355,388 |
| Open | 13.97 |
| Previous Close | 14.12 |
| Day's Range | 13.97 - 14.66 |
| 52-Week Range | 2.62 - 65.80 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 45.33 (+215.23%) |
| Earnings Date | May 13, 2026 |
About VOR
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2;... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for VOR stock is "Buy." The 12-month stock price target is $45.33, which is an increase of 215.23% from the latest price.
News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the ...
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease
Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's Disease
First and only dual BAFF/APRIL inhibitor in primary Sjögren's disease, one of the largest autoimmune diseases without an approved therapy First and only dual BAFF/APRIL inhibitor in primary Sjögren's ...
What's Behind The Jump In Vor Biopharma Stock?
The clinical-stage biotechnology company entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at $14.05 per share. Vor Bio anticipates the gross proceeds from the ...
Vor Bio Announces $75 Million Private Placement with TCGX
BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a s...
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and o...
Vor Biopharma Transcript: TD Cowen 46th Annual Health Care Conference
Telitacicept, a BAFF/APRIL inhibitor, is advancing in global phase III trials for myasthenia gravis and Sjögren's disease, showing best-in-disease efficacy and a strong safety profile. The company is well-funded through 2028 and targets multi-billion dollar markets in both indications.
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting an...
Vor Biopharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
A strategic pivot to autoimmune diseases is underway, with telitacicept as the lead asset showing strong efficacy and safety in large patient populations. Global Phase 3 trials in myasthenia gravis and Sjögren's are advancing, supported by a $450M cash runway and a seasoned leadership team.
Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting an...
Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announce...
Vor Bio Announces $150 Million Private Placement
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a se...
Vor Biopharma Transcript: Evercore ISI 8th Annual HealthCONx Conference
Management highlighted strong late-stage data for their BAFF/APRIL inhibitor in MG and Sjögren's, with plans to start a global phase 3 for Sjögren's next year. They aim to address high placebo rates in global trials and have a $300M cash runway to fund key milestones.
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities
Vor Biopharma Transcript: TD Cowen Immunology and Inflammation Summit
Bispecific BAFF/APRIL targeting enables broad B cell modulation with strong efficacy in Sjogren's and gMG, supported by robust phase III data and a balanced safety profile. Commercial focus is on leading in gMG and building the Sjogren's market, with $315M in cash funding operations through mid-2027.
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the p...
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today annou...
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile
Vor Bio to Participate in Upcoming Investor Conferences
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in t...
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sok...
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activit...
Vor Biopharma Transcript: Study Update
A robust phase III study in China showed telitacicept significantly improved systemic and symptomatic outcomes in primary Sjögren’s disease, with a strong safety profile and no confounding background therapies. The dual BAFF/APRIL mechanism offers a new benchmark for efficacy and positions the therapy for global expansion.
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a...
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025
CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data ...